Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 988

Results For "IT"

10131 News Found

Dr Reddy’s relaunch Naproxen Sodium Tablets in the US
News | August 04, 2021

Dr Reddy’s relaunch Naproxen Sodium Tablets in the US

It is part of the company’s pain/analgesics portfolio of OTC products


Mindpeers launches on-demand behavioural healthcare platform
Healthcare | August 04, 2021

Mindpeers launches on-demand behavioural healthcare platform

It is designed to tackle mental health issues


Alkem launch two drugs in US
News | August 04, 2021

Alkem launch two drugs in US

Ibuprofen and Famotidine tablets approved by FDA


NATCO Pharma transfers Lenalidomide ANDA to Arrow
News | August 04, 2021

NATCO Pharma transfers Lenalidomide ANDA to Arrow

Arrow is the marketing partner in US


Aartas launches co-working space for doctors under Clinishare
Healthcare | August 04, 2021

Aartas launches co-working space for doctors under Clinishare

Startup receives US $ 5 million in first round of funding


Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | August 03, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.


Abbott's Freestyle Libre 2 Ios App Cleared In U.S
Drug Approval | August 03, 2021

Abbott's Freestyle Libre 2 Ios App Cleared In U.S

FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms


NPPA caps prices on five medical devices effective July 20th 2021
Policy | August 03, 2021

NPPA caps prices on five medical devices effective July 20th 2021

The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers


Healthium Medtech acquires SGK Lab’s AbGel gelatin business
Healthcare | August 03, 2021

Healthium Medtech acquires SGK Lab’s AbGel gelatin business

Complementary business models are the reason for the acquisition


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials